Previous 10 | Next 10 |
Tafasitamab sold to Incyte Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash Shareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024 Novar...
2024-02-05 17:02:22 ET Novartis ( NYSE: NVS ) said it will acquire cancer drugmake r MorphoSys AG ( MOR ) for EUR 68/share, or an aggregate of EUR 2.7B.... Read the full article on Seeking Alpha For further details see: Novartis to buy cancer drugmaker Mo...
2024-02-05 16:32:27 ET More on Cytokinetics Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout ...
2024-02-05 13:05:53 ET More on Mid-day movers $ stocks. Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade) Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Peraso Inc. (PRSO) Q3 2023 Earnings Ca...
MorphoSys AG (NASDAQ: MOR) is one of today's top gainers. The company's shares have moved -3.78% on the day to $11.07. MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from ...
2024-02-05 10:24:24 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys expects 20...
2024-02-03 12:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-30 03:41:22 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys gains amid...
Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Anticipated 2024 OpEx in the range of &...
2024-01-26 11:18:29 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys climbs aft...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...